NCT07020260View on ClinicalTrials.gov

The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2028

Conditions
LeukemiaLymphoma
Interventions
OTHER

CAR T-cell and Cellular Therapies

A single IV infusion of huCAR 19 T-cells on day 0. In phase I 3 dose levels are tested to determine the RP2D.

Trial Locations (2)

3584 CX

University Medical Center Utrecht, Utrecht

3584CS

Princess Máxima Center for pediatric oncology, Utrecht

Sponsors

Collaborators (1)

Miltenyi Biomedicine GmbH
All Listed Sponsors
collaborator

Dutch Cancer Society

OTHER

collaborator

Miltenyi Biomedicine GmbH

INDUSTRY

collaborator

University Medical Center Utrecht (UMCU)

UNKNOWN

lead

Princess Maxima Center for Pediatric Oncology

OTHER